<DOC>
	<DOCNO>NCT01274338</DOCNO>
	<brief_summary>This randomized phase III trial study ipilimumab see well work compare high-dose interferon alfa-2b treating patient high-risk stage III-IV melanoma remove surgery . Monoclonal antibody , ipilimumab , may interfere ability tumor cell grow spread . Interferon alfa-2b may interfere growth tumor cell slow growth melanoma cancer . It yet know whether ipilimumab effective interferon alfa-2b treating patient melanoma .</brief_summary>
	<brief_title>Ipilimumab High-Dose Interferon Alfa-2b Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate recurrence-free survival ( RFS ) patient randomize receive post-operative adjuvant ipilimumab give either 10 mg/kg ( high dose ipilimumab ; HIP ) 3 mg/kg ( low dose ipilimumab : LIP ) versus randomize receive high-dose interferon alfa-2b ( HDI ) utilize hierarchical design assess HIP versus HDI first LIP versus HDI second ( first comparison significant ) . II . To evaluate overall survival ( OS ) patient randomize receive post-operative adjuvant ipilimumab give either 10 mg/kg ( HIP ) 3 mg/kg ( LIP ) versus randomize receive HDI utilize hierarchical design assess HIP versus HDI first LIP versus HDI second ( first comparison significant ) . SECONDARY OBJECTIVES : I . To evaluate safety tolerability post-operative adjuvant ipilimumab therapy give either 10 mg/kg ( HIP ) 3 mg/kg ( LIP ) . II . Among patient enrolled Clinical Community Oncology program ( CCOPs ) , compare global quality life ( QOL ) ipilimumab arm versus HDI use Functional Assessment Cancer Therapy ( FACT ) -General ( G ) form evaluate effect treatment-related side effect may impact health-related domain QOL use Functional Assessment Chronic Illness Therapy ( FACIT ) -diarrhea ( D ) FACT-biological response modifier ( BRM ) . OUTLINE : Patients age &gt; = 18 randomized Arms A , B , C patient age 12-17 randomized Arms D , E , F. ARM A : Patients receive induction high-dose ipilimumab intravenously ( IV ) 90 minute day 1 . Treatment repeat every 21 day total 4 course absence disease progression unacceptable toxicity . Beginning week 24 , patient receive maintenance high-dose ipilimumab IV 90 minute day 1 . Treatment repeat every 90 day maximum 4 course absence disease progression unacceptable toxicity . ( close accrual 4/4/14 ) ( adult accrual complete Arms A , B , C 8/15/2014 ) ARM B : Patients receive induction high-dose recombinant interferon alfa-2b IV 20 minute day 1-5 , 8-12 , 15-19 , 22-26 absence disease progression unacceptable toxicity . Patients receive maintenance high-dose recombinant interferon alfa-2b subcutaneously ( SC ) day 1 , 3 , 5 . Treatment repeat every week 48 week absence disease progression unacceptable toxicity . ( adult accrual complete Arms A , B , C 8/15/2014 ) ARM C : Patients receive induction low-dose ipilimumab IV 90 minute day 1 . Treatment repeat every 21 day total 4 course absence disease progression unacceptable toxicity . Beginning week 24 , patient receive maintenance low-dose ipilimumab IV 90 minute day 1 . Treatment repeat every 90 day maximum 4 course absence disease progression unacceptable toxicity . ( adult accrual complete Arms A , B , C 8/15/2014 ) ARM D : Patients receive induction high-dose ipilimumab IV 90 minute day 1 . Treatment repeat every 21 day total 4 course absence disease progression unacceptable toxicity . Beginning week 24 , patient receive maintenance high-dose ipilimumab IV 90 minute day 1 . Treatment repeat every 90 day maximum 4 course absence disease progression unacceptable toxicity . ARM E : Patients receive induction high-dose recombinant interferon alfa-2b IV 20 minute day 1-5 , 8-12 , 15-19 , 22-26 absence disease progression unacceptable toxicity . Patients receive maintenance high-dose recombinant interferon alfa-2b SC day 1 , 3 , 5 . Treatment repeat every week 48 week absence disease progression unacceptable toxicity ARM F : Patients receive induction low-dose ipilimumab IV 90 minute day 1 . Treatment repeat every 21 day total 4 course absence disease progression unacceptable toxicity . Beginning week 24 , patient receive maintenance low-dose ipilimumab IV 90 minute day 1 . Treatment repeat every 90 day maximum 4 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 3 month 2 year , every 6 month 3 year , yearly 15 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>All patient must diseasefree status document complete physical examination image study within 4 week prior randomization ; image study must include total body positron emission tomography ( PET ) compute tomography ( CT ) scan ( without brain ) brain magnetic resonance imaging ( MRI ) CT ( MRI contraindicate ) ; PETCT do , CT neck , chest , abdomen , pelvis do If reason CT do , MRI may do instead ; image study perform ( eg , bone scan ) must show evidence disease Patients must primary cutaneous melanoma belong one follow American Joint Commission Cancer ( AJCC ) stage ( 2009 AJCC Melanoma Staging System ) : Stage IIIB T14b N1a M0 T14b N2a M0 T14b N1b M0 T14b N2b M0 T14b N2c M0 Stage IIIC T14b N1b M0 T14b N2b M0 T14b N2c M0 Any T N3 M0 Stage IV M1a M1b NOTE : patient stage IV melanoma must normal lactate dehydrogenase ( LDH ) either distant skin , subcutaneous , lymph node , lung metastasis , visceral metastasis order eligible ; patient resect stage IV melanoma , LDH within institutional upper limit normal ( ULN ) must document within 4 week prior randomization Patients disease recurrence adequate surgical excision original primary cutaneous/unknown primary melanoma allow even n't fit strict stag criterion , follow : Recurrence regional lymph node basin prior complete lymph node dissection ; relapse disease must completely surgically resect free margin Recurrence form intransit satellite metastasis distant skin/subcutaneous , nodal , lung metastasis completely surgically resect free margin Recurrence regional lymph node basin ; relapse disease must completely surgically resect free margin Patients unknown primary melanoma ( Tx ) present cutaneous , subcutaneous , nodal and/or lung metastases completely surgically resect free margin allow ; patient allow even n't fit strict stag criterion ; stage IV patient LDH within institutional ULN must document within 4 week prior randomization ( M1c eligible ) NOTE : subject classify IIIB , IIIC , M1a M1b include subject disease recurrence adequate surgical excision original primary melanoma ; treat team/physician investigator review overall TNM status ( include primary tumor presentation disease recurrence status ) provide designation IIIB , IIIC , M1a M1b Patients must randomize within 84 day ( 12 week ) surgical resection ; one surgical procedure require render patient diseasefree , patient must randomize within 12 week last surgery NOTE : patient clinically positive lymph node melanoma involvement positive lymph node identify lymphoscintigraphic and/or dye lymphographic technique groin , axilla , neck additional lymphadenectomy site ; complete lymph node dissection procedure would consider last surgery count 84 day unless subsequent surgical procedure ( ) clinically required ensure disease free status Patients must receive adjuvant treatment ( chemotherapy , biotherapy , limb perfusion ) resection ( ) make ( ) eligible trial NOTE : previous radiation therapy , include surgical resection , allow long 21 day elapse radiation initiation adjuvant systemic therapy Prior treatment anticytotoxic Tlymphocyte antigen 4 ( CTLA4 ) monoclonal antibody prior CTLA4 inhibitor agonist prior cluster differentiation ( CD ) 137 agonist prior interferonalfa allow ; form prior treatment melanoma ( e.g. , aldesleukin [ IL2 ] , antitumor vaccine , chemotherapy ) allow give resection ( ) make ( ) patient eligible trial , must complete least 4 week prior randomization Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Patients must active infection require current treatment parenteral antibiotic Patients must significant medical , surgical , psychiatric condition require medication treatment opinion investigator may interfere compliance , make administration ipilimumab HDI hazardous obscure interpretation adverse event ( AEs ) , condition associate frequent diarrhea ; patient baseline frequent diarrhea ( e.g . irritable bowel syndrome ) eligible Patients carefully screen depression baseline indication history depression strongly recommend patient closely follow together behavioral health psychiatric medical support ; patient establish diagnosis depression , assessment investigator may make administration interferon ( IFN ) alfa ipilimumab hazardous , enrolled protocol ; risk benefit treat standard adjuvant IFNalfa weigh carefully consultation behavioral health psychiatry Patients must document history inflammatory bowel disease ( include ulcerative colitis Crohn 's disease ) diverticulitis ( history diverticulosis allow ) Patients must autoimmune disorder condition immunosuppression require current ongoing treatment systemic corticosteroid ( systemic immunosuppressant ) , include oral steroid ( i.e. , prednisone , dexamethasone ) continuous use topical steroid cream ointment ophthalmologic steroid ; history occasional ( continuous ) use steroid inhaler allow ; replacement dos steroids patient adrenal insufficiency allow ; patient discontinue use class medication least 2 week prior randomization eligible , judgment treat physician investigator , patient likely require resumption treatment class drug study Exclusion study also include patient history symptomatic autoimmune disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , Sj√∂gren 's syndrome , autoimmune vasculitis [ e.g. , Wegener 's granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( e.g. , GuillainBarre syndrome Myasthenia Gravis ) ; central nervous system ( CNS ) autoimmune disease ( e.g. , poliomyelitis , multiple sclerosis ) Patients autoimmune hypothyroid disease type I diabetes replacement treatment eligible Patients must infectious disease vaccination ( e.g. , standard influenza , H1N1 influenza , pneumococcal , meningococcal , tetanus toxoid ) within 4 week prior randomization Patients must prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness Patients current malignancy eligible ; patient malignancy eligible continuously disease free &gt; 5 year prior time randomization ; patient prior history time situ cancer , lobular carcinoma breast situ , cervical cancer situ , atypical melanocytic hyperplasia melanoma situ eligible ; patient prior history basal squamous skin cancer eligible ; patient multiple primary melanoma eligible Women must pregnant breastfeeding ; female childbearing potential must blood test urine study screen rule pregnancy NOTE : woman childbearing potential ( WOCBP ) woman , regardless sexual orientation whether undergone tubal ligation , meet follow criterion : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) ; postmenopause define : Amenorrhea &gt; = 12 consecutive month without another cause , For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum follicle stimulate hormone ( FSH ) level &gt; = 35 mIU/mL WOCBP must use adequate method contraception avoid pregnancy throughout study 26 week last dose ipilimumab HDI , manner risk pregnancy minimize ; woman use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( e.g. , vasectomy ) consider childbearing potential Men father potential WOCBP must use adequate method contraception avoid conception/pregnancy throughout study 26 week last dose ipilimumab HDI manner risk pregnancy minimize ; men WOCBP unwilling unable strictly follow requirement eligible WOCBP eligible satisfy following : A positive pregnancy test baseline Pregnant breastfeed White blood cell ( WBC ) &gt; = 3,000/uL Absolute neutrophil count ( ANC ) &gt; = 1,500/uL Platelets &gt; = 100 x 10^3/uL Hemoglobin &gt; = 10 g/dL Serum creatinine = &lt; 1.5 mg/dL Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) = &lt; 2.5 x ULN Serum bilirubin = &lt; 1.5 x ULN , ( except patient Gilbert 's syndrome , must total bilirubin less 3.0 mg/dL ) No active chronic infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C ; patient must negative test HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) within 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>